Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Refractory/Recurrent Anti-NMDAR/Anti-LGI1 Encephalitis
NCT06510283Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in Anti-N-methyl-D-aspartate receptor encephalitis, anti-LGI1 encephalitis (LGI1-AE), sponsored by Beijing Tongren Hospital. Started Dec 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Anti-N-methyl-D-aspartate receptor encephalitisanti-LGI1 encephalitis (LGI1-AE)
Beyond the preview
Go deeper on NCT06510283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510283.